期刊
FRONTIERS IN ONCOLOGY
卷 11, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2021.703318
关键词
lung squamous carcinoma; ROS1 rearrangement; crizotinib; atypical imaging manifestation; hypoalbuminemia
类别
ROS1 rearrangements are rare in lung squamous cell carcinoma, but can be effectively targeted with crizotinib. Clinicians should consider testing for ROS1 rearrangements and using crizotinib in the treatment of lung squamous cell carcinoma.
ROS1 rearrangements have been identified as driver mutations, accounting for 1-2% of lung adenocarcinoma, but are extremely rare in case of lung squamous cell carcinoma. In this work, we report a lung squamous cell carcinoma in a patient with peripheral lung cancer radiological manifestation, harboring ROS1 rearrangement, with high sensitivity to crizotinib. Our findings suggest that clinicians should pay more attention toward the occurrence of ROS1 rearrangements and the application of crizotinib for lung squamous cell carcinoma treatment.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据